Mabwell (Shanghai) Bioscience Co., Ltd.: Neoplasms trials

The registry lists 13 Neoplasms studies with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 13Phase 2 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid TumorsNot yet recruitingNCT06947226Phase 1/2
• 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological TumorsNot yet recruitingNCT06926998Phase 1/2
• A Study of 7MW3711 in Subjects With Advanced Solid TumorsRecruitingNCT06008379Phase 1/2
• A Phase 1/2 Study of 7MW3711 in Advanced Solid TumorsRecruitingNCT06008366Phase 1/2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid TumorsNot yet recruitingNCT05911984Phase 1
• A Clinical Study of 9MW2821 in Advanced Malignant Solid TumorsRecruitingNCT05773937Phase 1
• A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid TumorsRecruitingNCT05216965Phase 1/2
• Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid TumorsActive, not recruitingNCT05990452Phase 1/2
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy SubjectsCompletedNCT05740475Phase 1
• 6MW3511 in Patients With Advanced Solid TumorStatus unknownNCT05524194Phase 1/2
• A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid TumorsSuspendedNCT05416749Phase 1/2
• A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant NeoplasmStatus unknownNCT05048160Phase 1/2
• Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid TumorsStatus unknownNCT04478461Phase 1